ABNCoV2
ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic. On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects. References 

Clinical trials related to COVID-19
Danish COVID-19 vaccines
Virus-like particle vaccines